| |
Newsroom /
Health and Fitness
/
Health and Fitness
/
Osteoporosis - Pipeline Assessment and Market Forecasts to 2017
Osteoporosis - Pipeline Assessment and Market Forecasts to 2017
The Osteoporosis Therapeutics Market is Forecast to Grow Significantly to 2017
Hyderabad,
AP,
India
(prbd.net)
21/10/2010
The global osteoporosis therapeutics market was valued at $9.6 billion in 2009. It is expected to grow to $18.2 billion by 2017 at a Compound Annual Growth Rate (CAGR) of 8.2%. This significant growth is primarily attributed to the strong current treatment options as well as strong pipeline candidates. An increase in the prevalence of osteoporosis among the female population is the principal driver of the osteoporosis market and will continue to be in the future. The significant reason for the increase in
prevalence is due to the decline in the use of Hormone Replacement Therapy (HRT) in healthy postmenopausal women. HRT has been used to help prevent the bone loss that leads to osteoporosis. However, recent negative study results, showing an increased risk of heart attacks, stroke, breast cancer and blood clots, have led to a decline in HRT usage. Therefore, a decline in the use of HRT and an increase in the diseased population will combine to contribute to the increased burden of osteoporosis.
GlobalData has analyzed the current market landscape and found it to be strong. Antiresorptive and bone-forming drugs are the two classes that are used for the treatment of osteoporosis. Bisphosphonates,calcitonin, estrogen and estrogen agonists/antagonists are the major antiresorptive agents available in the market. The above classes include alendronate (Fosamax), risedronate (Actonel), ibandronate (Bonivia),zoledronic acid (Reclast) and raloxifene (Evista). The market is currently dominated by antiresorptive
drugs. However, new bone-forming agents are being developed by researchers and are expected to be available by 2015. Products available in the market for the treatment of osteoporosis are at the lower side of the efficacy spectrum. There is a need for a product which meets the clinical end points. Products such as Fosamax and Reclast are very safe but still lack efficacy to meet the desired clinical outcome.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Osteoporosis-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
The poor diagnosis of the disease is a major barrier for the osteoporosis market. One of the major reasons why osteoporosis is under-diagnosed is that most vertebral and pelvic fractures are asymptomatic and therefore go unrecognized by patients and physicians. Even patients with clinically apparent fragility fractures are overlooked, with fewer than 5% of patients with osteoporotic fractures being referred for medical evaluation and treatment. The majority of patients with fragility fractures are not referred for further evaluation and treatment. Studies have shown that older women and men with hip
fractures do not receive follow-up drug treatment.
GlobalData, the industry analysis specialist, has released its new report, “Osteoporosis – Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global osteoporosis therapeutics market. The report identifies the key trends shaping and driving the global osteoporosis therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global osteoporosis sector.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Osteoporosis-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|